Pfizer at #ESMO24 (Credit: Ayisha Sharma for Endpoints News)
September 14, 2024 08:45 AM EDTUpdated September 15, 01:49 PM
R&D

Pfiz­er tees up Phase 3 test in weight man­age­ment — but in an un­ex­pect­ed area

Kyle LaHucik

Senior Reporter

BARCELONA — At a ma­jor can­cer con­fer­ence, Pfiz­er made an un­ex­pect­ed an­nounce­ment: It has late-stage plans in weight man­age­ment. But it’ …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

All of 23and­Me's in­de­pen­dent board mem­bers re­sign over dis­agree­ments with CEO

Bad trip: How cul­ture con­flict and a need for cash near­ly broke Lykos

Af­ter land­ing a key win in a com­mon can­cer con­di­tion, Pfiz­er faces a big test in Phase 3

No­var­tis’ Kisqali snags FDA ap­proval to re­duce re­cur­rence in pa­tients with ear­ly forms of breast can­cer

Mer­ck and Dai­ichi’s re­ject­ed HER3 ADC clears a Phase 3 in cer­tain lung can­cers

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times